Overview

Join us to deliberate the latest challenges and opportunities resulting from EMA, Health Canada and National Institutes of Health data disclosure & transparency policies, and gain insights on different approaches to navigate and comply with global disclosure and transparency requirements for medicinal products and medical devices.

We will also discuss the impact of the EU General Data Protection Regulation (GDPR) on data sharing; various strategies for preparing for the implementation of the EU Clinical Trials Regulation; the impact of Brexit on MHRA and disclosure requirements; how new ICMJE data sharing requirements are being implemented; what approaches sponsors are taking for redaction and anonymization; and updates on sponsor compliance.

This 2019 Conference builds on prior conference discussions and leverages learnings from Regulators and international experts in the field.

Featured topics

Legal Requirements for disclosure of Clinical Research Information
EU Clinical Trial Regulation requirements for trial results summaries for laypersons
Clinical Trial Disclosure and Transparency Requirements in the Upcoming EU Medical Device Regulation
Legal impact of the EU General Data Protection Regulation (GDPR) on data sharing
Operationalizing ICMJE’s data sharing requirement - How sponsors are approaching data sharing/Experience to date from the ICMJE
Latest update from ClinicalTrials.gov
Planning for submission of clinical documents to Health Canada and EMA
Understanding approaches sponsors are taking on redaction and anonymization
Impact of Brexit on MHRA and clinical trial disclosure requirements

Featured

Want to learn more about Clinical Trial Disclosure & Data Transparency Conference? You've come to the right site!

Exhibits

Learn more

Exhibits

Learn more

Who should attend?

Professionals and experts from areas affected by public clinical trial disclosure requirements across drug and medical device development (regulatory affairs, scientific affairs, medical writing, clinical operations, medical communication, biostatisticians/biometrics, project management, medical affairs, legal, patent departments, etc.)
Consultants, CROs and companies that offer services for submitting to clinical trial registries, publication planning and medical writing
Patient organisations
Regulatory agencies
Academic institutions

Learning objectives

Learn about the latest developments relating to EMA’s Clinical Data Publication Policy 0070, Health Canada’s Clinical Data Publication Policy, ICMJE Data Sharing Statement Requirement, EU MDR, EU GDPR, Brexit and MHRA, and ClinicalTrials.gov from regulators, legal experts as well as industry experts.
Benefit from the various perspectives on regulatory, legal aspects and practical challenges from large to smaller sponsor organisations
Leverage best practices on the practical implementation through case studies by the exchanging of views between regulators, industry, patients, academia and other stakeholders
Use a unique opportunity for networking and asking questions to your own specific situation and area of responsibility

Short Course or Primer

To keep you at the forefront.

Dec 03, 2019

The Evolving Disclosure/Transparency Landscape (Workshop):

Learn more

Dec 03, 2019

The Evolving Disclosure/Transparency Landscape (Workshop):

Learn more

Program Committee

Julie G. Holtzople Senior Director Clinical Transparency and Data Sharing
AstraZeneca, United States
Merete Joergensen, MBA, MSc Clinical Disclosure and Transparency Expert, Former EFPIA, CREG Clinical Trials
Merete-J Consulting CVR: 34920818, Denmark
Scott Feiner Senior Manager, Trial Disclosure
AbbVie, United States
Robert Paarlberg, MS Principal
Paarlberg & Associates LLC, United States
Matthias Zerm, PhD Lead Expert, Clinical Trial Disclosure and R&D Processes
Germany